7,511.15

+134.29

+1.82%

52,044.20

+758.47

+1.48%

25,140.55

+561.12

+2.28%

2,807.73

+53.62

+1.95%

4.8550

-0.0040

-0.08%

21.52

-4.12

-16.07%

4,125.40

+50.50

+1.24%

74,774.55

-1,191.99

-1.57%

Crude Oil Dec 26

87.47

-3.36

-3.70%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Curanex Pharmaceuticals Inc (CURX)

6.21 0.00 (0.00%)

As of November 6 at 4:00:00 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

GlobeNewswire 5mo ago

CURX
0.00%
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

GlobeNewswire 7mo ago

CURX
0.00%
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

GlobeNewswire 7mo ago

CURX
0.00%
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

GlobeNewswire 6mo ago

CURX
0.00%
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

GlobeNewswire 7mo ago
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

GlobeNewswire 7mo ago
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

GlobeNewswire 7mo ago
Curanex Forms World Class Scientific Advisory Board

GlobeNewswire 8mo ago
Curanex Provides Operational Update on Key Regulatory Milestones

GlobeNewswire 8mo ago

Performance Overview

Return	CURX	S&P 500 (^GSPC)
YTD	-6.19%	+7.76%
1-Year	-49.35%	+9.77%
3-Year	-91.83%	+68.96%

Mobilize your Website

View Site in Mobile | Classic

Share by: